Loading company…
Madrigal Pharmaceuticals is a Pennsylvania-based biopharmaceutical company developing a liver-directed therapy for NASH.
Madrigal Pharmaceuticals, Inc. is based in Pennsylvania, US, and was founded in 2016 by CMO Rebecca Taub. It is listed on Nasdaq under the ticker MDGL and develops a liver-directed thyroid hormone receptor (THR) beta-selective agonist for non-alcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. The therapy is in Phase 3 trials for patients with compensated cirrhosis. In March 2024 the company raised USD 195 million in a private placement of 750,000 shares at USD 260 each on the Nasdaq Global Select Market.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in